Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Predicted Market Size Of The Anti-Inflammatory Biologics Industry By 2029?

The market size for anti-inflammatory biologics has been witnessing substantial growth in the recent past. It is projected to expand from $108.11 billion in 2024 to $118.02 billion in 2025, at a compound annual growth rate (CAGR) of 9.2%. Factors such as increasing cases of arthritis, heightened awareness of autoimmune diseases, the introduction of new biologic treatments, enhanced healthcare infrastructure, and an uptick in regulatory approvals contribute to the growth observed during the historical period.

In the coming few years, the anti-inflammatory biologics market size is anticipated to experience robust growth. The market is projected to reach $166.28 billion by 2029, with a compound annual growth rate (CAGR) of 9.0%. This growth over the forecast period could be credited to factors like the growing adoption of biologics, a surge in demand for targeted therapies, an uptick in patient preference for lasting remission, and expanded uses of biomarkers for tracking diseases, along with an increased demand for personalized medicine. The forecast period is also expected to witness trends such as progression in the development of biologic drugs, the creation of oral biologics to combat inflammation, advancement in drug delivery systems driven by technology, developments in the field of biosimilars, and enhancements in diagnostic tools.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp

Which Factors Are Steering Growth In The Anti-Inflammatory Biologics Market?

The growth of the anti-inflammatory biologics market is anticipated to be driven by the increasing incidence of arthritis. This condition, marked by inflammation or swelling of one or more joints leading to pain, stiffness, and limited movement, often diminishes with age. The primary contributor to the growing incidence of arthritis is the rising rate of obesity, as excess body weight exerts more pressure on joints, resulting in inflammation and joint degradation. Anti-inflammatory biologics are beneficial in arthritis treatment as they target precise components of the immune system to decrease inflammation, mitigate joint damage, alleviate symptoms, and enhance physical functionality and life quality for individuals with moderate to severe arthritis. For example, data from the Office for Health Improvement and Disparities, a UK government body, indicated that in 2022, 17.6% of individuals aged 16 and older were suffering from a chronic MSK disorder such as arthritis or persistent back or joint issues, a rise from the 17.0% recorded in 2021. Consequently, the growing prevalence of arthritis is propelling the expansion of the anti-inflammatory biologics market.

Which Segment Accounts For The Largest Share In The Anti-Inflammatory Biologics Market?

The anti-inflammatory biologics market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous

3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes

Subsegments:

1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol

2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors

3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab

4) By T-Cell Inhibitors: Abatacept, Alefacept

5) By Other Drug Classes: Janus Kinase Inhibitors, Phosphodiesterase-4 Inhibitors, Sphingosine 1-Phosphate Receptor Modulators, Anti-IgE And Other Biologics

Which Long-Term Trends Will Play A Crucial Role In The Anti-Inflammatory Biologics Market?

Leading firms in the anti-inflammatory biologics market are prioritizing the creation of novel solutions like interleukin-6 (IL-6) receptor antagonists. These offer a more specific approach and fewer side effects for chronic inflammatory illnesses. Biologic drugs, like these IL-6 receptor antagonists, function by inhibiting the IL-6 receptor and thus mitigating inflammation and the immune response in conditions like rheumatoid arthritis. In February 2023, for instance, the US-based biotechnology firm, Regeneron Pharmaceuticals Inc., received US Food and Drug Administration (FDA) approval for Kevzara. This is the first and only biologic treatment for polymyalgia rheumatica (PMR) patients who don’t respond well to corticosteroids. Kevzara, a completely human monoclonal antibody, blocks the IL-6 receptor and combats PMR-associated inflammation. PMR is a disease leading to muscular pain and rigidity, most often in the elderly. Unlike common steroids that may lead to osteoporosis and diabetes with long-term use, Kevzara offers a more direct, steroid-conserving tactic which can result in better patient results and superior long-term safety.

Who Are The Dominant Players In The Anti-Inflammatory Biologics Market Today?

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc., Regeneron Pharmaceuticals Inc, Biogen Inc., UCB S.A, UCB S.A./N.V, Swedish Orphan Biovitrum AB, Almirall S.A., Evotec SE, Hansa Biopharma AB.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report

What Regional Factors Are Accelerating Growth In The Anti-Inflammatory Biologics Market?

North America was the largest region in the anti-inflammatory biologics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25695&type=smp

Browse Through More Reports Similar to the Global Anti-Inflammatory Biologics Market 2025, By The Business Research Company

Rheumatology Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Wound Care Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wound-care-biologics-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model